FDA Approved: AMBRISENTAN — Supplemental Application (Cipla USA Inc.)

View source ↗

Summary

FDA approved a supplemental application for Ambrisentan from Cipla USA Inc. under ANDA 210715.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Pulmonary Arterial Hypertension

Drugs mentioned

• Ambrisentan (Ambrisentan)

Snippet

SUPPL AP for AMBRISENTAN (AMBRISENTAN)